Transgene Biotek – Breakthrough in the oral delivery of children’s injectable vaccines
Transgene Biotek informed the exchange that in their ongoing studies at one of the premier institutes in India on the oral delivery of injectable Tetanus vaccine, demonstrated excellent antibody titres. This is potentially an exciting development on the global immunization program.
“We endeavour to advance this technology, after completion of the present study, for delivering other vaccines also such as Diphtheria, Pertussis, Hepatitis B etc currently administered to infants, children and adults only through injectable route.” – the disclosure read.
The global vaccines market was estimated to be around US$28.0 Bn in 2016 and is expected to reach a value of around US$48.0 Bn by 2025.
The company is striving to unlock values of such developments through a subsidiary/SPV at an appropriate time on the conclusion of the remaining studies.
Financial health of Transgene Biotek –
Although Transgene Biotek has been facing several serious and adverse challenges during the last few years, but the company is working hard to continue with the R&D program and the current development is a testament to that.
The current market cap of Transgene Biotek is Rs.16.75 Crores. In FY17, the company did a sales of Rs. 0.28 Crores and reported a loss of Rs. 19.68 Crores.
Want to keep a 360-degree watch on the stock market? Well, keyword tracker can be of some use for you. Create multiple keyword alerts and get notified whenever those keywords appear in any BSE Corporate announcement. Check the details here – https://www.viewstocks.in/keyword_tracker
Also see, how keyword tracker helped me find my next investment idea – Welspun Enterprise. Details here.